secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011878
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises
---------------------------------------------------------------------------

- Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
- Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.
- Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.
- Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/0001641172-25-011878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer